open access

Vol 72, No 3 (2021)
Editorial
Published online: 2021-06-30
Submitted: 2021-05-17
Accepted: 2021-05-17
Get Citation

The treatment of heterozygous familial hypercholesterolemia — a local perspective

Łukasz Bułdak
DOI: 10.5603/EP.a2021.0055
·
Pubmed: 34292576
·
Endokrynologia Polska 2021;72(3):189-190.

open access

Vol 72, No 3 (2021)
Editorial
Published online: 2021-06-30
Submitted: 2021-05-17
Accepted: 2021-05-17

Abstract

none

Abstract

none

Get Citation

Keywords

familial hypercholesterolemia; lipid lowering therapy; PCSK9; alirocumab; evolocumab

About this article
Title

The treatment of heterozygous familial hypercholesterolemia — a local perspective

Journal

Endokrynologia Polska

Issue

Vol 72, No 3 (2021)

Article type

Editorial

Pages

189-190

Published online

2021-06-30

DOI

10.5603/EP.a2021.0055

Pubmed

34292576

Bibliographic record

Endokrynologia Polska 2021;72(3):189-190.

Keywords

familial hypercholesterolemia
lipid lowering therapy
PCSK9
alirocumab
evolocumab

Authors

Łukasz Bułdak

References (13)
  1. Dyrbuś K, Gąsior M, Desperak P, et al. The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals. Atherosclerosis. 2019; 288: 33–41.
  2. Haase A, Goldberg AC. Identification of people with heterozygous familial hypercholesterolemia. Curr Opin Lipidol. 2012; 23(4): 282–289.
  3. Krajowe Centrum Hipercholesterolemii Rodzinnej. http://hipercholesterolemia.com.pl/Kontakt,67 (11.05.2021).
  4. Bułdak Ł, Marek B, Kajdaniuk D, et al. Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol Pol. 2019; 70(6): 511–519.
  5. Hennig M, Brandt-Varma A, Wołoszyn-Durkiewicz A, et al. Monitoring the Effects of Hypolipidemic Treatment in Children with Familial Hypercholesterolemia in Poland. Life (Basel). 2020; 10(11).
  6. Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021 [Epub ahead of print].
  7. Zygmunt A, Dąbrowski J, Lewiński A. Specialist thyroid package 1 (PS1) in outpatient endocrine care. Endokrynol Pol. 2020; 71(6): 485–496.
  8. Leczenie inhibitorami PCSK-9 pacjentów z zaburzeniami lipidowymi (ICD-10 E78.01, I21, I22, I25). https://www.gov.pl/attachment/9ad24526-c366-4b32-b4b0-8eb9a62c9d00 (11.05.2021).
  9. Brandts J, Dharmayat K, Vallejo-Vaz A, et al. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021; 325: 46–56.
  10. Cordero A, Rodríguez-Mañero M, Fácila L, et al. Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials. J Diabetes Metab Disord. 2020; 19(2): 759–765.
  11. Okopień B, Bułdak Ł, Bołdys A. Current and future trends in the lipid lowering therapy. Pharmacol Rep. 2016; 68(4): 737–747.
  12. Banach M, Duell PB, Gotto AM, et al. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020; 5(10): 1124–1135.
  13. Surma S, Romańczyk M, Filipiak KJ. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiol J. 2021 [Epub ahead of print].

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl